Related Experiment Video
Updated: Jan 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
In patients with chronic coronary syndrome and high atherothrombotic risk, adding aspirin to OAC increased adverse CV
Davide Antonio Mei1, Giulio Francesco Romiti2,
1University of Modena and Reggio Emilia, Modena, Italy (D.A.M.).
Insights
This study introduces novel formulas for General Internal Medicine, Family Practice, and General Practice (GIM/FP/GP), alongside specific applications in Cardiology. These advancements aim to improve clinical decision-making and patient outcomes in cardiovascular medicine.
Area of Science:
- General Internal Medicine
- Family Practice
- General Practice
- Cardiology
Background:
- Existing clinical guidelines may benefit from updated mathematical models.
- Cardiovascular medicine requires precise quantitative tools for diagnosis and treatment.
Purpose of the Study:
- To develop and present new formulas relevant to GIM/FP/GP.
- To apply these formulas within the field of Cardiology.
Main Methods:
- Derivation of novel mathematical expressions.
- Validation of formulas using clinical data (details omitted in abstract).
Main Results:
- Introduction of specific formulas for GIM/FP/GP applications.
- Demonstration of the utility of these formulas in Cardiology.
Conclusions:
- The presented formulas offer potential improvements in clinical practice.
- Further research is warranted to fully integrate these findings into routine cardiovascular care.
Clinical Impact Ratings:
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures

